Life-course social and economic inequalities in non-communicable disease prevalence: the Tromsø Study (2015–2016)
Scandinavian Journal of Public Health · 16.06.2026
DOI: 10.1177/14034948261453066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scandinavian Journal of Public Health, online erschienen am 16.06.2026. Verfasst von Rebecca A Hetland und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim
To systematically examine associations between six inequality indicators from different life-course domains and the adult prevalence of six non-communicable diseases (NCDs) within a Nordic population-based study.
Methods
We conducted a cross-sectional analysis using data from the seventh Tromsø Study survey (2015–2016) in Norway. All residents aged ⩾40 years were invited (65% participation). Age-adjusted, sex-stratified logistic regression models were used to assess associations between inequality indicators (parental and own educational level, childhood economic status, adverse childhood experiences (ACEs), income, and subjective occupational status) on continuous 0–1 cumulative proportion scales, and NCDs (major adverse cardiovascular events (MACE), cancer, chronic obstructive pulmonary disease (COPD), diabetes, musculoskeletal symptoms, and mental distress). Odds ratios (ORs), with 95% confidence intervals (CIs), were estimated, where OR >1 indicates higher odds of an NCD with greater disadvantage.
Results
Among 21,069 participants, greater social and economic disadvantage was associated with higher odds of MACE, COPD, diabetes, musculoskeletal symptoms, and mental distress. For musculoskeletal symptoms, significant associations were observed across all inequality indicators in both sexes. The steepest gradients were observed in mental distress for ACEs in women (OR 7.81, 95% CI 6.20–9.86) and men (10.09, 7.34–13.88). In contrast, greater disadvantage was associated with lower odds of cancer for some indicators; sensitivity analyses indicated these findings reflected cancer types with known positive socioeconomic gradients.
Conclusions
Life-course social and economic disadvantage was consistently associated with higher prevalence of MACE, COPD, diabetes, musculoskeletal symptoms, and mental distress, with the pattern and magnitude varying across inequality indicators and NCDs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
- Department of Health and Care Sciences, UiT The Arctic University of Norway, Tromsø, Norway.
- Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.
- Department of Psychology, UiT The Arctic University of Norway, Tromsø, Norway.
ORCID-Profile: Rebecca A Hetland, Laila A Hopstock, Inger Ariansen
Zitieren
APA
Hetland, R. A., Wilsgaard, T., Hopstock, L. A., Ariansen, I., Johansson, J., Jacobsen, B. K., Thimm, J. C., Wang, C. E. A., & Grimsgaard, S. (2026). Life-course social and economic inequalities in non-communicable disease prevalence: the Tromsø Study (2015–2016). Scandinavian Journal of Public Health. https://doi.org/10.1177/14034948261453066
Vancouver
Hetland RA, Wilsgaard T, Hopstock LA, Ariansen I, Johansson J, Jacobsen BK, et al. Life-course social and economic inequalities in non-communicable disease prevalence: the Tromsø Study (2015–2016). Scandinavian Journal of Public Health. 2026. doi:10.1177/14034948261453066
BibTeX
@article{Hetland2026,
author = {Hetland, Rebecca A and Wilsgaard, Tom and Hopstock, Laila A and Ariansen, Inger and Johansson, Jonas and Jacobsen, Bjarne K and Thimm, Jens C and Wang, Catharina E Arfwedson and Grimsgaard, Sameline},
title = {Life-course social and economic inequalities in non-communicable disease prevalence: the Tromsø Study (2015–2016)},
journal = {Scandinavian Journal of Public Health},
year = {2026},
doi = {10.1177/14034948261453066}
}
EUVIMED